Kazakhstan's domestically developed cancer drug DVC, currently in the second phase of clinical trials, is moving toward registration. If all procedures are completed on schedule, the drug could be registered in Kazakhstan as early as next year, according to infohub.kz.
Minister of Science and Higher Education Sayasat Nurbek said at a government briefing: "We are now determining the dosage and how the body reacts to higher and lower doses. We will try to complete all these trials by the end of this year and submit the drug for pre-registration."
After the trials are completed, the results must undergo expert review, after which the drug can be submitted for state registration. Nurbek noted that the developers are at the penultimate stage before registration.
Initially, the drug is planned to be registered for use in Kazakhstan and the countries of the Eurasian Economic Union. Entering other markets will require separate registration according to the rules of those countries.
However, it is worth noting that in 2025 the drug was also planned to be registered by the end of the year, but that did not happen, so delays cannot be ruled out.
Clinical trials of the domestic drug DVC on humans began in March 2026. Earlier, the developers reported successful preclinical studies on animals. In May, Sayasat Nurbek announced that the first phase of human trials had been completed: all study participants survived, and approximately 30% of patients saw a reduction in tumors.
Currently, specialists are determining the optimal dosage of the drug and assessing patients' reactions to different doses. For now, it is only about clinical trials. Before registration, the drug must undergo the required procedures for assessing safety, quality, and efficacy.